CRL – Charles River Laboratories International, Inc.
CRL — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
7.73
Margin Of Safety %
28
Put/Call OI Ratio
0.79
EPS Next Q Diff
0.51
EPS Last/This Y
14.05
EPS This/Next Y
1.11
Price
159.18
Target Price
202.46
Analyst Recom
1.94
Performance Q
-21.66
Upside
-140.9%
Beta
1.63
Ticker: CRL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-02 | CRL | 178.56 | 0.22 | 0.04 | 15472 |
| 2026-03-04 | CRL | 179.56 | 0.22 | 0.01 | 15280 |
| 2026-03-05 | CRL | 181.27 | 0.23 | 0.46 | 14911 |
| 2026-03-09 | CRL | 177.01 | 0.24 | 0.16 | 14530 |
| 2026-03-10 | CRL | 167.37 | 0.24 | 0.18 | 14380 |
| 2026-03-11 | CRL | 168.92 | 0.25 | 1.33 | 14621 |
| 2026-03-12 | CRL | 152.68 | 0.25 | 0.01 | 14633 |
| 2026-03-17 | CRL | 153.6 | 0.23 | 0.04 | 12926 |
| 2026-03-18 | CRL | 157.15 | 0.24 | 0.58 | 12824 |
| 2026-03-19 | CRL | 152.97 | 0.24 | 1.74 | 12843 |
| 2026-03-20 | CRL | 153.59 | 0.23 | 0.83 | 12845 |
| 2026-03-23 | CRL | 158.09 | 0.80 | 0.00 | 4279 |
| 2026-03-24 | CRL | 159.26 | 0.79 | 0.13 | 4288 |
| 2026-03-25 | CRL | 165.26 | 0.78 | 0.55 | 4340 |
| 2026-03-26 | CRL | 165.18 | 0.78 | 3.33 | 4345 |
| 2026-03-27 | CRL | 159.14 | 0.79 | 4.54 | 4373 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | CRL | 178.56 | -17.4 | 653.5 | 11.02 |
| 2026-03-02 | CRL | 178.49 | -17.4 | 566.9 | 11.03 |
| 2026-03-03 | CRL | 175.51 | -17.4 | 639.1 | 11.03 |
| 2026-03-04 | CRL | 179.57 | -17.4 | 659.5 | 11.03 |
| 2026-03-05 | CRL | 181.29 | -17.4 | 653.0 | 11.02 |
| 2026-03-06 | CRL | 174.42 | -17.4 | 628.5 | 11.02 |
| 2026-03-09 | CRL | 177.16 | -17.4 | 656.1 | 11.03 |
| 2026-03-10 | CRL | 167.39 | -15.6 | 620.1 | 11.15 |
| 2026-03-11 | CRL | 168.95 | -15.6 | 652.9 | 11.15 |
| 2026-03-12 | CRL | 152.68 | -17.4 | 599.0 | 11.17 |
| 2026-03-13 | CRL | 155.57 | -17.4 | 657.6 | 11.17 |
| 2026-03-17 | CRL | 153.63 | -17.5 | 653.6 | 11.14 |
| 2026-03-18 | CRL | 157.17 | -17.5 | 659.3 | 11.14 |
| 2026-03-19 | CRL | 152.94 | -17.5 | 476.4 | 11.14 |
| 2026-03-20 | CRL | 153.60 | -17.5 | 487.6 | 11.14 |
| 2026-03-23 | CRL | 157.91 | -17.5 | 497.0 | 11.14 |
| 2026-03-24 | CRL | 159.19 | -17.5 | 489.2 | 11.14 |
| 2026-03-25 | CRL | 165.89 | -17.5 | 502.4 | 11.14 |
| 2026-03-26 | CRL | 165.18 | -17.5 | 484.8 | 11.14 |
| 2026-03-27 | CRL | 159.18 | -17.5 | 472.6 | 11.14 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | CRL | -0.06 | 4.90 | 6.08 |
| 2026-03-02 | CRL | -0.06 | 5.27 | 6.08 |
| 2026-03-03 | CRL | -0.06 | 5.27 | 6.08 |
| 2026-03-04 | CRL | -0.06 | 5.27 | 6.08 |
| 2026-03-05 | CRL | -0.06 | 5.27 | 6.08 |
| 2026-03-06 | CRL | -0.06 | 5.27 | 6.08 |
| 2026-03-09 | CRL | -0.06 | 5.10 | 6.08 |
| 2026-03-10 | CRL | -0.06 | 5.10 | 6.08 |
| 2026-03-11 | CRL | -0.06 | 5.10 | 7.28 |
| 2026-03-12 | CRL | -0.06 | 5.10 | 7.28 |
| 2026-03-13 | CRL | -0.06 | 5.10 | 7.28 |
| 2026-03-17 | CRL | -0.06 | 5.30 | 7.28 |
| 2026-03-18 | CRL | -0.06 | 5.30 | 7.28 |
| 2026-03-19 | CRL | -0.06 | 5.30 | 7.28 |
| 2026-03-20 | CRL | -0.06 | 5.30 | 7.28 |
| 2026-03-23 | CRL | -0.06 | 5.29 | 7.28 |
| 2026-03-24 | CRL | -0.06 | 5.29 | 7.28 |
| 2026-03-25 | CRL | -0.06 | 5.29 | 7.73 |
| 2026-03-26 | CRL | -0.06 | 5.29 | 7.73 |
| 2026-03-27 | CRL | -0.06 | 5.29 | 7.73 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.39
Avg. EPS Est. Current Quarter
1.93
Avg. EPS Est. Next Quarter
2.9
Insider Transactions
-0.06
Institutional Transactions
5.29
Beta
1.63
Average Sales Estimate Current Quarter
980
Average Sales Estimate Next Quarter
985
Fair Value
203.44
Quality Score
47
Growth Score
53
Sentiment Score
92
Actual DrawDown %
65.4
Max Drawdown 5-Year %
-78.2
Target Price
202.46
P/E
Forward P/E
13.14
PEG
1.46
P/S
1.95
P/B
2.48
P/Free Cash Flow
15.11
EPS
-2.96
Average EPS Est. Cur. Y
11.14
EPS Next Y. (Est.)
12.25
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-3.59
Relative Volume
0.85
Return on Equity vs Sector %
-31.9
Return on Equity vs Industry %
-15.6
EPS 1 7Days Diff
EPS 1 30Days Diff
0.25
EBIT Estimation
472.6
◆
CRL
Healthcare
$159.16
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
43.1
Range 1M
27.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
7.8%
EPS NY
9.3%
52W%
48.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+48.4% upside
Upside
+48.4%
Quality
47
MoS
28%
Charles River Laboratories InteSector: Healthcare
Industry: Diagnostics & Research
Employees: 18300
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
CRL
Latest News
—
Caricamento notizie per CRL…
stock quote shares CRL – Charles River Laboratories International, Inc. Stock Price stock today
news today CRL – Charles River Laboratories International, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CRL – Charles River Laboratories International, Inc. yahoo finance google finance
stock history CRL – Charles River Laboratories International, Inc. invest stock market
stock prices CRL premarket after hours
ticker CRL fair value insiders trading